Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Marek Health vs RxSpan MD

Marek Health
Graded #173

Lower grade

vs+19.89999999999999
RxSpan MD
Graded #4

Higher grade

The verdict

RxSpan MD takes it — 86.8/100 to 66.9/100.

RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A physician-led telehealth under board-certified founder Dr. John Diaz with a broad GLP-1 menu — compounded semaglutide and tirzepatide by injection or oral capsule, plus a brand-name lane and microdosing — on transparent all-inclusive pricing to all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRxSpan MD +41
45
86
Dose & formulationRxSpan MD +49
40
89
Clinical oversightMarek Health +5
93
88
Labs & monitoringMarek Health +14
97
83
FulfillmentRxSpan MD +5
84
89
Contract termsRxSpan MD +30
55
85
Marek Health · left barRxSpan MD · right bar

The numbers

MetricMarek HealthRxSpan MD
WeighScore66.9/10086.8/100
GradeCB
Scorecard rank#173#4
SemaglutideNot disclosedFrom $194/mo
TirzepatideNot disclosed$329/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Marek Health

Graded #173 · C

Strengths

  • Lab panels are core: initial comprehensive labs + 6–12 week follow-up + ongoing every 6 months — rare among GLP-1 providers
  • Dedicated Health Coach paired with each client alongside partnered licensed physician as standard Proactive Care Team
  • All 50 US states served; 100% telehealth with routine physician check-ins every 6 months built into the program
  • Human optimization framing attracts pragmatic patients; partnered physicians selected for data-driven, high-leverage mindset
  • No set subscription plan — custom protocol built around client health goals with option to cancel anytime

Where it loses points

  • Pricing fully gated — no published rates; intake assessment required before quotes, limiting upfront comparison shopping
  • Annual in-person physical required from own PCP or urgent care (every 12 months) — not provided by Marek Health
  • No LegitScript certification found; platform explicitly disclaims being a healthcare clinic, which reduces regulatory trust signals
  • Weight loss is one of many services alongside TRT, hair, brain focus, sexual health — not a dedicated GLP-1 platform
  • Compounded vs. brand medication details not disclosed publicly — medication type determined post-intake with partnered physician
RxSpan MD

Graded #4 · B

Strengths

  • Available in all 50 states
  • Transparent, all-inclusive published pricing — consult, medication, supplies, shipping and support, cancel anytime, from ~$194/mo compounded semaglutide on an annual plan
  • Both injectable and a real oral (capsule) route, plus compounded and an advertised brand-name lane
  • Physician-led by a named, board-certified founder (Dr. John Diaz) with 24/7 messaging and coaching

Where it loses points

  • Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
  • Published pricing is for the compounded line — brand-name pricing isn’t itemized
  • A prescription isn’t guaranteed — a provider reviews eligibility after checkout

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard